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Abstract: 
 
Autophagy is responsible for the degradation of cytoplasmic components and organelles 
such as mitochondria. The selective degradation of damaged mitochondria by autophagy 
is termed mitophagy, and is an important quality control mechanism. Neurons, being 
highly specialized cells, are particularly susceptible to defects of autophagy. Impairments in 
mitochondrial function and their dynamics are present in many neurodegenerative diseases, 
and modulators of both mitochondrial physiology and autophagy present themselves as 
promising therapeutic targets. Zebrafish are now established as a valuable tool for disease 
modelling. A wide variety of genetic and molecular techniques can be employed to highlight 
pathogenic processes and dissect disease pathways. This review will explore the role that 
zebrafish have so far played in our understanding of mitophagy in neurodegeneration, and 
will discuss how they might be used to drive the wider mitophagy field forward.  
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1. Mitophagy is important for mitochondrial quality control. 
 
Mitophagy is the process by which mitochondria are selectively degraded by the highly 
conserved autophagic machinery. It occurs during developmental processes in specialized 
cells such as erythrocytes, while in other cell types damaged mitochondria are removed in 
order to maintain a functional mitochondrial population. Mitochondria are membrane-bound 
organelles with several important roles in cellular function, including energy production by 
oxidative phosphorylation, calcium homeostasis, and the metabolism of fatty acids, amino 
acids and steroids. They are also the primary source of potentially damaging endogenous 
reactive oxygen species (ROS), which have been linked to neurodegeneration,1 and can 
induce protein carbonyls, lipid peroxidation and DNA damage.
2
 Importantly, release of 
cytochrome c from mitochondria triggers apoptosis, and so the clearance of damaged 
mitochondria is vital for cell survival. ROS are also able to increase the release of 
cytochrome c and induce the mitochondrial permeability transition pore (mPTP), both of 
which activate apoptosis.
3
  
 3 
To prevent cellular damage from faulty mitochondria a number of protective 
mechanisms have evolved; for example, mitochondria have an endogenous proteolytic 
mechanism to degrade misfolded proteins,
4
 proteins located on the inner and outer 
membranes can be degraded in the cytosol by the ubiquitin-proteasome system (UPS) and 
also specific mitochondrial components can be sequestered and directed to lysosomes for 
degradation by autophagy.
5
 Furthermore, electron microscopy analysis has revealed that 
entire mitochondria are detectable in both yeast vacuoles and mammalian lysosomes.
6,7
 It is 
this selective degradation of mitochondria by autophagy that is now termed mitophagy.  
 Autophagy is responsible for the degradation of cytoplasmic components and 
organelles. At least three distinct autophagic mechanisms have been identified that present 
substrates to the lysosome; macroautophagy, microautophagy and chaperone-mediated 
autophagy. Macroautophagy is a tightly regulated process to ensure that cytosolic 
components are not inappropriately removed; it requires the formation of a double 
membrane called the phagophore, which expands and fuses to form a vesicle called an 
autophagosome that sequesters regions of cytosol containing proteins and organelles to be 
degraded.
8
 Autophagosomes do not themselves contain degradative enzymes and so must 
fuse with lysosomes containing a range of acid hydrolases to form a structure referred to as 
an autolysosome. For many years macroautophagy was considered to be a nonselective bulk 
degradation process, but it now seems clear that there exist very selective subtypes of 
macroautophagy, which occur during nutrient-rich conditions to remove damaged organelles 
or toxic aggregates.
9
 These selective pathways, including mitophagy, are mediated by 
autophagic adapter proteins.
10
 
 In this review, the focus is upon the study of mitophagy and its involvement in 
neurodegeneration using zebrafish as a model system. Defective autophagy has been 
associated with neurodegeneration,
11
 and mutations in PTEN induced putative kinase 1 
(PINK1),
12
 the most common cause of recessive Parkinson disease (PD), have highlighted 
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the contribution of mitophagy to neurodegeneration. The study of mitophagy using in vivo 
models of neurodegeneration and relating them to normal mitochondrial biology will be 
essential to help understand disease mechanisms, and the advantageous features of the 
zebrafish position it as a tool to help move the mitophagy field forward.  
2. What makes zebrafish a useful model to study the role of mitophagy in normal tissue 
and during neurodegeneration? 
In recent years zebrafish have become a valuable tool for the study of vertebrate 
embryogenesis and disease modelling. Zebrafish develop rapidly, externally to the mother, in 
high numbers and are optically transparent, features not presented by mammalian systems. 
Neurogenesis commences approximately 10 h post fertilization (hpf) and is followed by 
synaptogenesis approximately 6 h later.
13
 By 24 hpf brain morphogenesis is well advanced
14
 
and by 3 days post fertilization (dpf) the majority of morphogenesis is complete.
15
 
Characteristic body movements commence at around 17 hpf,
16
 at 21 hpf (when manually 
removed from their chorions) they become responsive to touch,
16
 at 52 hpf they hatch,
13
 and 
at 4 dpf swim to pursue food particles.
17
 Most zebrafish genes share 50-80% sequence 
identity
13
 with human counterparts, their genome has been sequenced and, although not fully 
annotated, is available on bioinformatics databases. As demonstrated using PINK1 as an 
example, amino acid sequences are also well conserved and often more so in functional 
domains (Fig. 1).  
 The molecular mechanisms of autophagy are evolutionarily conserved from yeast to 
mammal
18
 and genomic databases make it relatively easy to identify orthologous genes 
known to be involved in autophagy and, more specifically, mitophagy (Table 1). 
 Such a degree of conservation implies that these genes and processes are fundamental 
to the growth and maintenance of the organism. Manipulation of these genes is relatively 
easy in zebrafish compared to other vertebrates, therefore providing a good opportunity to 
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dissect these pathways. Their transparency makes them particularly amenable to targeted 
reporter transgene expression, including autophagy-related genes
19
 or vital dyes such as 
LysoTracker, a stain that can be used to visualize lysosomes in live zebrafish.
20
 Several 
neurodegenerative diseases have been modelled in zebrafish by expressing mutant forms of 
the human disease gene under the control of a zebrafish promoter. Examples of these genes 
include MAPT,
21,22
 SOD1
23
 and HTT.
24
 Fusion of green fluorescent protein (GFP) to the 
disease-causing transgene can be used to monitor the clearance of protein aggregates,
24
 and a 
similar approach of fluorescently tagging mitochondrial proteins can be used to monitor 
mitophagy in an intact organism under a variety of conditions. Highlighting this proposal, 
Plucinska et al. have recently developed a zebrafish line expressing fluorescently tagged 
mitochondria specifically in sensory neurons.
25
 This model allows the researcher to follow 
mitochondrial flux in single axons using time-lapse microscopy. Given that expression of the 
fluorescent mitochondrial tag is GAL4 dependent, these so-called MitoFish can be crossed to 
any suitable GAL4-driver line,
26
 thereby enabling expression in other cells and tissues. For 
information on GAL4-driver lines the ZFIN database provides a useful resource. A further 
advantage of the zebrafish is the fact that due to their rapid, external development, disease 
phenotypes tend to manifest in the larval stages (by 5 dpf) and so data can be obtained 
quickly. Typically the generation time for laboratory zebrafish is 3 months and a pair of 
zebrafish are able to produce up to 300 embryos weekly; this allows statistically significant 
sample sizes to be used at a substantially lower cost than mammalian systems.  
 
2.1 How representative of humans is the zebrafish brain? 
The zebrafish brain can be divided into the same regions as other vertebrates, consisting of 
the telencephalon, diencephalon, mesencephalon, metencephalon and myelencephalon.
14
 
Furthermore, zebrafish neurons possess typical structural features, including the soma, 
dendrites and the axon, which can be myelinated or demyelinated. Astrocytes,
27
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oligodendrocytes
28
 and microglia
29,30
 have all been positively identified in the zebrafish 
brain. The identification of these cell types is important because their interactions with 
neurons and their involvement in disease processes is becoming increasingly relevant, and 
these in vivo interactions are something that cannot be easily replicated in vitro. The 
development of the blood brain barrier (BBB) in zebrafish has been shown by 3 dpf,
31
 an 
important finding when considering the screening of potential therapeutics to modulate 
mitophagy and its involvement in neurodegeneration. Typically, upon development of the 
BBB, only lipophilic molecules with a diameter smaller than 500 daltons are able to pass 
through,
32
 which severely restricts the accessibility of the brain to drugs. Permeability tests 
on the zebrafish BBB revealed similar properties to that of mammals,
31
 confirming that 
zebrafish are a suitable model in which to test drugs destined for the brain or to test novel 
ways of escorting potential therapeutics to the brain.  
Several regions of the zebrafish central nervous system, including the cerebellum, 
optic tracts and tectum, medulla, hypothalamus and cranial nerves, show structural similarity 
to the corresponding human structures.
33
 Additionally, the main neurotransmitter systems 
involving acetylcholine, dopamine, GABA, glycine, glutamate, noradrenaline and serotonin 
are all present.
34
 With reference to PD, a disorder in which mitophagy has been implicated, 
although dopaminergic (DA) neurons are identifiable by 18-20 hpf,
35
 they are not present in 
the zebrafish midbrain; however, the observation of Parkinsonian traits in zebrafish treated 
with a DA neuron-selective toxin implies the existence of functionally equivalent circuitry. 
Axonal tracing shows axons ascending from the DA neurons of the ventral diencephalon to 
the striatum in the zebrafish, and these could be considered homologous to the nigrostriatal 
system.
36
 The schematic presented in Figure 2 below highlights the zebrafish dopaminergic 
system, and for an excellent exploration of the zebrafish catecholaminergic system see 
Kastenhuber et al.
37
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2.2 Zebrafish are amenable to high throughput drug screens. 
A considerable advantage of the zebrafish model system is as a tool to develop and screen 
candidate drugs and provide in vivo toxicity testing of new compounds, with the potential to 
treat human neurological disease. The ability to house larvae in 96-well plates facilitates 
high-throughput screening using definable, and in some cases automatable, phenotypic 
endpoints, such as locomotor behaviors or the monitoring of fluorescent reporters. These 
attributes of zebrafish are a huge advantage over the slow and expensive process used when 
testing compounds in mammals. Similarly, the application of pharmacological modulators of 
the autophagic pathway may be applied in a high-throughput manner by simply adding 
compounds to the fish water. Given that a cell-based drug screen does not provide adequate 
toxicity data and may produce hundreds of “hits” requiring validation, this provides a 
considerable advantage over cellular models. A further advantage of using an in vivo model 
over conventional target-based drug design is that small molecule screens can be carried out 
prior to understanding the molecular basis or pathways involved in disease. The use of 
zebrafish in the drug discovery process has been reviewed in Williams and Hong,
38
 and 
Kaufman et al. have provided a protocol and review of zebrafish chemical screens.
39
 
 
2.3 What molecular tools are available to manipulate the zebrafish genome? 
The use of oligonucleotide-based reagents confers a genetic method by which to interrogate 
and disrupt the function of genes putatively involved in mitophagy. While this work has been 
performed widely in cells, similar studies have seldom been carried out in vivo, and utilizing 
zebrafish would be significantly faster and cheaper than mammals. Several antisense 
knockdown technologies have been explored,
40-43
 but the primary method in zebrafish is 
through morpholino oligonucleotides (MOs). MOs are usually injected into the 1- to 4-cell 
embryo so that they become distributed throughout the animal as it develops. By designing 
MOs to span the start codon, translation can be blocked by inhibiting the procession of the 
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initiation complex.
44
 Additionally, MOs can be designed to target intron/exon splice 
junctions to produce splice variants either lacking specific domains within proteins of 
interest or to introduce a frame-shift, producing an in-frame stop codon.
45
 Splice-blocking 
MOs have the advantage that because they do not affect the maternal transcript, a target gene 
with maternal function can be examined.
46
 To confirm MO specificity, it is prudent to 
perform a BLAST search of the MO sequence and to resequence the target of the 
experimental line to ensure that no single-nucleotide polymorphisms or sequence errors in 
the reference sequence are present.  
 When using MOs, it is important to demonstrate how effective knockdown has been. 
MOs targeted to the start codon provide a simple and effective approach; it can, however, be 
difficult to demonstrate that protein expression is reduced.
47
 This can be achieved by whole-
mount immunohistochemistry, but this relies on there being an antibody available to the 
protein of interest that is reactive to the zebrafish protein in vivo. Western blotting may also 
be used, but depending on antibody sensitivity a large number of animals may be required. In 
the absence of antibodies, GFP-tagged mRNA for the transcript of interest may be injected 
into an embryo along with the MO. If the MO successfully produces knockdown, then less 
fluorescence will be observed.
48
 This technique does, however, assume that the endogenous 
mRNA is equally accessible to the MO. The advantage of splice-inhibiting MOs is the ability 
to test exactly what missplicing event has occurred by using RT-PCR and sequencing of the 
spliced product.  
 Injection of MOs at early developmental stages causes constitutive knockdown, but 
caution must be taken to ensure that the observed phenotype is not due to off-target effects. 
Suitable controls could be: i) injection of nonsense oligos, ii) a sense version of the 
experimental oligo, or iii) a mismatched oligo. Since none of these pseudo MOs will be able 
to bind to the target sequence, any observed effects can be assumed to be nonspecific. 
However, in our view, the ability to observe consistent phenotypes with multiple MOs (e.g., 
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translation blocking, splice site) directed against a given target is a more valid control. 
Examples of nonspecific effects include neurodegeneration,
49
 more widespread cell death
50
 
and epibolic failure.
51
 As a further test of specificity, co-injection of a wild-type target 
mRNA can be used to see if the morphant phenotype can be rescued. The issues here are 
threefold: i) this mRNA will now also be a target for translation-blocking MO knockdown; 
ii) it is optimistic to assume that this injected mRNA will be correctly translated in the cells 
of interest; and iii) the protein translated from the injected mRNA is found in ectopic places 
and may cause a phenotype that hampers interpretation of the rescue experiment. To resolve 
the issue of knockdown of the injected mRNA by translation-blocking MOs, transcripts can 
be engineered to include mismatches, preventing the annealing of the MO. The design of 
these resistant transcripts can be aided by the use of software such as Gene Designer.
52
 
Alternatively, splice-site MOs can be used, which do not typically recognize spliced 
mRNAs.  
 A disadvantage of MO use is their dilution as the embryo grows, so they only act for 
a few days. To inhibit gene expression in later stages it is possible to use photoactivatable 
MOs
53,54
 but these have only been available since June 2012 and so data concerning their use 
is limited.  
 While being a powerful technique, transient knockdown by MO may be insufficient 
in some cases, and the development of permanent genetic knockouts is desirable. Zinc finger 
nucleases (ZFNs)
55
 may present a different approach to investigate putative genes involved 
in mitophagy. Perhaps the biggest advantage of these nucleases over MOs is their ability to 
confer robust germ line genetic alterations, with the ability to generate heterozygous carriers 
of a mutation in 6-8 months.
56
 ZFNs are derived from a fusion of a Cys2 Hys2 zinc finger 
protein with the type IIS Fok1 endonuclease. Each finger recognizes a 4 base pair DNA 
sequence via an α-helical domain. Using molecular engineering, several fingers can be 
linked in tandem to allow site-specific recognition.
57
 Cleavage is then initiated by the 
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endonuclease domain at the site determined by the zinc finger protein. Specificity is derived 
by the requirement for two ZFNs to bind the same locus in a specific orientation, to create a 
double-strand break. Eukaryotic cells may then implement double-strand break repair 
mechanisms. These include nonhomologous end joining and homology-directed repair.
58
 
Religation by nonhomologous end joining tends to result in the loss or gain of small amounts 
of sequence, typically resulting in a frameshift allele. Importantly, ZFNs have recently been 
used to introduce sequence-specific knockins in both rats and mice.
59
 However, there are 
specificity issues and not all sequences can be targeted.  
 Recently a new tool for genome editing has been used with very promising results, 
consisting of a transcription activator-like effector fused to the Fok1 endonuclease, referred 
to as TALENs. Compared to ZFNs, TALENs are more predictable and specific.
60
 TALENs 
are constructed to work in pairs, the specificity of which is encoded in their central 
consecutive repeat domain. Each repeat corresponds to one DNA base pair, and the di-amino 
acid motif repeats at the hyper-variable positions 12 and 13 determine sequence specificity.
60
 
TALENs cause targeted double-stranded DNA breaks with high efficiency
61
 and can be 
designed to target any specific DNA sequence; moreover, they have been successfully tested 
in zebrafish.
61
 TALENs provide a new way to not only knockout genes, but also show 
promise as a means to knockin disease genes at a specific locus, with the first successful 
modification of the zebrafish genome through homology-directed repair, including the 
insertion of a predefined donor sequence, being recently reported.
62
 The TALEN technology 
is publicly available,
63
 is affordable and can be constructed with relative ease in-house.  
2.4 How can zebrafish mutagenesis screens be exploited? 
Zebrafish mutagenesis screens have produced recessive mutations resulting in remarkable 
phenotypes, the research of which has added much to the field of developmental biology 
(detailed information on many of these mutants is available in a dedicated edition of 
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Development, 1996; 123). These forward genetic screens provide a way to observe the 
cellular and molecular events involved in normal development, physiology, behavior and 
disease. In order to find mutants with defects in mitophagy, interested laboratories may wish 
to use the tools referred to in this paper to identify mitophagy mutants and then, through 
linkage analysis, clone the causative gene (for a guide to positional cloning in zebrafish see 
Zhou and Zon).
64
 It is also interesting to note that recent technological advances mean that 
mutation identification may be considerably sped up, in a cost-effective manner, by using 
whole genome sequencing and homozygosity mapping.
65,66
 Information on zebrafish mutant 
lines and their availability is accessible through the Zebrafish International Resource Centre 
(ZIRC), the Zebrafish Mutation Project and the Tübingen zebrafish stock collection.  
 To speed up this process the reverse genetic technique, Targeting Induced Local 
Lesions IN Genomes (TILLING), may be chosen. This contrasts with forward genetic 
screens because, rather than finding a phenotype of interest and then seeking to discover in 
what gene the mutation lies, specific genes in lines generated by random mutagenesis are 
requested to be targeted for sequencing, irrespective of phenotype.
67,68
 The advantage of 
TILLING lies in its ability to detect mutations in genes with subtle phenotypes that affect 
mitophagy and may therefore be undetectable by forward genetic screens. For further 
information on TILLING methods and its successes, readers are directed to an excellent 
review by D. Stemple.
69
 Requests for genes to be screened by TILLING can be submitted to 
the FHCRC Zebrafish TILLING Project, while the Sanger Institute is now exome 
sequencing all their mutants and uploading new alleles to their website; requests to receive 
alerts on new alleles can be registered online. There are, however, limitations to the N-ethyl-
N-nitrosourea (ENU) approach; for example, some genes are less likely to be mutagenized 
by random mutagenesis due to their small size, and some genes may be more or less likely to 
undergo mutation depending on their nucleotide composition
70
 (Table 2).  
 12 
3. Oxidative stress can damage mitochondria. 
3.1 Oxidative stress can trigger the mitochondrial permeability transition. 
 
A byproduct of energy production by oxidative phosphorylation in mitochondria is the 
production of ROS. Oxidation of DNA, proteins or lipids may cause cellular damage, and 
ROS accumulation in mitochondria risks mitochondrial DNA (mtDNA) mutation, lipid 
peroxidation and opening of the mPTP and inner membrane anion channel.
71
 Cells may 
respond in a graded fashion to the opening of the mPTP, an event that leads to dissipation of 
the proton motive force, which results in the uncoupling of oxidative phosphorylation and 
reversal of the mitochondrial ATPsynthase.
72
 Furthermore, the permeability transition causes 
severe mitochondrial swelling, culminating in the rupture of the outer mitochondrial 
membrane. If only a few mitochondria are affected then mitophagy is induced, whereas if 
higher numbers of mitochondria are involved then apoptosis is promoted
72
 due to the 
mitochondrial release, upon rupture, of intermembrane proapoptotic factors such as 
cytochrome c, AIFM1 (apoptosis-inducing factor, mitochondrion-associated, 1) and 
DIABLO.
73
 Mitophagy can therefore act to protect cells from apoptosis by removing 
damaged organelles that would otherwise activate a caspase-dependent cell death. 
Interestingly, PINK1, a protein implicated in PD, regulates the release of Ca
2+ 
from the 
Na
+
/K
+
 exchanger, with its loss leading to a lowered threshold for the opening of the mPTP, 
resulting in increased apoptosis.
74
 
 Animal models thus far used to help understand the permeability transition have been 
uninformative, highlighting the fact that in order to understand permeability transition, more 
selective inhibitors are required, and to meet this need zebrafish would be an ideal drug 
discovery tool.
75
 On this basis, permeability transition in zebrafish has been characterised, 
and similar to the mammalian permeability transition, demonstrates Ca
2+
 dependency and 
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responds to the same modulators.
75
 These findings therefore establish the zebrafish as a 
suitable model to screen inhibitors of the permeability transition that is relevant to human 
disease.  
3.2 Oxidative stress can induce mitophagy. 
 
Conditions of oxidative stress induce the expression of BNIP3L/NIX, due to the action of 
HIF1A [hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription 
factor)].
76
 BNIP3L then binds BCL2 and BCL2L1 at the outer mitochondrial membrane, 
which causes the release of BECN1, to which they were previously bound to inhibit 
autophagy.; the release of BECN1 then activates the autophagic machinery.
76
 Although 
PINK1 and PARK2/PARKIN are necessary to tag mitochondria for recognition by the 
autophagic machinery, they do not induce autophagy itself; the latter is dependent on 
BNIP3L.
77
 Furthermore, carbonylcyanide m-chlorophenylhydrazone (CCCP)-induced 
production of ROS and consequent mitophagy only occurs in the presence of BNIP3L, and 
PARK2, ubiquitin and SQSTM1/p62 mitochondrial translocation are also BNIP3L 
dependent.
77
 The implications of these findings are that BNIP3L, being instrumental for 
CCCP-induced depolarization, can, in some circumstances, act upstream of the PINK1-
PARK2 pathway.
77
 BNIP3L is conserved in zebrafish and therefore presents a good target 
for knockdown studies (Table 1).  
3.3 Antioxidant trials in zebrafish. 
In neurodegenerative disease, ROS increase. Antioxidants have therefore been considered as 
potential treatments, yet zebrafish research indicates that using antioxidants as a treatment 
for neurodegeneration may in some instances be flawed. In zebrafish models of Huntington 
disease, antioxidants exacerbate the disease phenotype.
78
 Although reducing ROS, some 
antioxidants inhibit both basal and induced autophagy, thus increasing the levels of protein 
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aggregates. The potential benefits of ROS reduction must therefore be balanced against the 
possibility of increased aggregate formation. Given the fact that the role of protein 
aggregates in pathology is uncertain, zebrafish may be an ideal organism in which to study 
this further.  
 
4. How can zebrafish contribute to studies on the role of mitophagy in 
neurodegeneration? 
4.1 The mechanisms of mitophagy are conserved in zebrafish. 
Thus far, three models of mitophagy have been proposed; that identified in yeast,
79
 
mitochondrial removal during mammalian red blood cell development
80
 and that mediated 
by the PINK1-PARK2 pathway, identified by studies of Parkinson disease. 
81-85
 Mitophagy 
is also used to regulate the number of mitochondria according to metabolic requirements and 
as a method of quality control.  
 In yeast, the different steps required for autophagy are mediated by autophagy-related 
(Atg) proteins. Thus far, 33 ATG genes have been identified as being involved in 
autophagy,
86
 many of which are also involved in mitophagy, and  5 further genes, which are 
specific to mitophagy. What has become apparent is that only approximately 14 of these 
autophagy genes, and none of the mitophagy-specific genes, have a clear human ortholog.
87
 
To increase our understanding of autophagic processes and mitochondrial quality control, it 
will be important to either identify orthologs of the yeast proteins using novel methods, or 
study autophagy in higher eukaryotes such as zebrafish. 
 Those proteins involved in the core machinery of autophagy are conserved in 
mammals and most are essential for mitophagy.
88
 The fact that the bulk of these proteins are 
common to both autophagy and mitophagy raises the question of how the autophagosome is 
directed selectively to mitochondria. The majority of these proteins are required for both 
nonselective and selective autophagy, but in some cases specific proteins are required that 
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allow specific cargos to be identified for sequestration into autophagosomes. For example, it 
has recently been shown in yeast that the protein Atg32 is required to selectively tag 
mitochondria for autophagy, and that this protein is not required either for other types of 
selective or nonselective autophagy.
88
 Furthermore, Atg32 interacts with Atg8 and the 
scaffold protein Atg11, which recruit the mitochondria for delivery to the vacuole.
88
 Atg32 
expression is increased under oxidative stress, which implies it has a role in quality control; 
however, ATG32 null yeast appear to have no mitochondrial defects.
89
 According to the 
Ensembl genome browser, zebrafish possess eight homologs of ATG8: gabarapa, gabarap, 
gabarapl2, zgc92606, map1lc3c, map1lc3a, cr847510.1 and map1lc3b in decreasing order of 
homology. Unfortunately ATG32 and ATG11 do not have any easily identifiable homologs in 
higher organisms, although it is possible that proteins with similar roles do exist.  
 In development, removal of healthy mitochondria is necessary in certain instances. 
For example, mammalian red blood cells, the eye lens and mature sperm lack mitochondria 
due to their removal during the differentiation process. A protein identified as being required 
for mitophagy during development is BNIP3L, which was introduced above. This is a 
binding partner of the ubiquitin-like modifier proteins from the microtubule-associated 
protein 1 light chain 3 (MAP1LC3) and GABA receptor associated protein (GABARAP) 
family of ATG8 homologs, and ablation of this interaction abolishes mitochondrial clearance 
in murine reticulocytes.
90-93
 MAP1LC3 (known as map1lc3a, b and c in zebrafish) are 
homologs of the yeast gene ATG8, and one form of this protein, MAP1LC3-II 
(phosphatidylethanolamine modified MAP1LC3), is used to monitor autophagy because it 
localizes to autophagosomal membranes.
94
 GFP-MAP1LC3 is frequently used to assess 
autophagy and, if GFP-map1lc3 transgenic zebrafish were to be treated with a fluorescent 
mitochondrial stain such as MitoTracker, could be used to investigate mitophagy in live 
zebrafish. Two transgenic zebrafish lines expressing GFP-tagged versions of zebrafish 
Map1lc3b and Gabarapa have been developed and, as expected, accumulate in lysosomes on 
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drug challenge.
19
 This supports the use of zebrafish to monitor autophagy in vivo. 
Additionally, in zebrafish, gabarapa knockdown results in microcephaly,
95
 whereas the 
equivalent knockout mouse is phenotypically normal.
96
 This highlights the fact that zebrafish 
may be able to impart mechanistic detail unavailable in other systems.  
 It has been shown in zebrafish by monitoring the expression levels of Map1lc3b, that 
autophagosome synthesis is increased by the application of rapamycin and other autophagy 
inducers. Furthermore, this expression can be increased using drugs to inhibit lysosomal 
function, such as pepstatin A, E64d and ammonium chloride.
19
 In this same study, GFP 
tagged Map1lc3b and Gabarapa distribution was monitored, demonstrating the validity of the 
technique. Through the generation of transgenic mitochondrial reporter lines, perhaps 
crossed to map1lc3b or gabarapa knockout lines, mitochondrial dynamics could be observed 
during pharmacological or genetic manipulation, to shed further light on the role of 
mitophagy in neurodegeneration.  
 
4.2 Abnormal autophagy can lead to neurodegeneration. 
 
Macroautophagy may play a protective role in neurodegenerative diseases where proteins 
misfold and accumulate, such as Alzheimer
97
 and Huntington diseases,
24,78,98,99
 amyotrophic 
lateral sclerosis
100
 and PD.
101,102
 These diseases and others have been successfully modelled 
in zebrafish, and therefore these models represent an excellent opportunity in which to 
explore whether autophagy is defective and to modulate its activity in order to determine if 
this results in phenotypic improvement (Table 3).  
 On the basis that the upregulation of autophagy might be protective, zebrafish 
provide an ideal high-throughput model system for candidate drug screening. The drug 
lithium
103
 for example, is a potentially interesting autophagic upregulator. Despite its 
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potentially harmful off-target effects, it is an approved drug and is prescribed when 
alternatives are not effective. Lithium use in zebrafish has been successfully demonstrated to 
reduce TAU phosphorylation
104
 in a TAU transgenic zebrafish model, and so is worthy of 
investigation as an in vivo modulator of autophagy.  
4.3 Mutations in mitochondrial fusion and fission proteins cause neurodegeneration. 
 
Originally thought to be static structures, it is now clear that mitochondria are actually highly 
dynamic organelles that can move throughout the cell, undergo repeated cycles of fusion 
(whereby two mitochondria combine to form a single organelle) and fission (in which long 
tubular mitochondria split into two or more smaller fragments) and are selectively 
degraded.
105
 This dynamism allows mitochondrial networks to distribute mitochondria 
throughout the cell, respond to changes in the cellular environment and protect against 
mitochondrial dysfunction. Importantly, mitochondrial dynamics and mitophagy are closely 
related,
106,107
 with a shift in the balance from fusion to fission promoting mitochondrial 
clearance. 
 Fusion is associated with cell survival and aids in the process of maintaining 
mitochondrial protein quality control, mtDNA integrity and the redistribution of 
metabolites.
1
 For some years it has been known that fusion is mediated by both the outer 
mitochondrial membrane proteins mitofusin 1 and 2 (MFN1 and MFN2), which are 
dynamin-like GTPases, and the inner mitochondrial membrane protein, optic atrophy 1 
(OPA1).
108
 Mitochondrial depolarization promotes fragmentation due to the loss of OPA1
109
 
and MFN1/2.
110,111
 Evidence of the importance of mitochondrial dynamics is the fact that 
mutations in MFN2
112
 result in Charcot-Marie-Tooth disease type IIA, and OPA1 mutations 
cause dominant optic atrophy.
113
 mfn2 knockdown in zebrafish causes profound degeneration 
of motoneuron axons, but no alterations in mitochondrial morphology are observed.
67
 It is 
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possible that incomplete knockdown is insufficient to cause mitochondrial defects, but, if so, 
the implication is that the neuronal death is not being caused by mitochondrial defect. Given 
that Charcot-Marie-Tooth disease type IIA is a dominant disorder, it may be that 
haploinsufficiency (which would be modelled by partial knockdown) is not the cause, and 
instead mutant MFN2 causes a gain of function. Further study of this model may provide 
understanding of the role of MFN2.  
Mutations in a number of genes related to fusion and fission cause human 
neuropathies, and neurons with long axons such as sensory and motor neurons are 
particularly susceptible. Mitochondrial fission in mammals requires the large cytoplasmic 
GTPase DNM1L (dynamin 1-like) and FIS1 [fission 1 (mitochondrial outer membrane) 
homolog (S. cerevisiae)].
114
 The formation of synapses demands large amounts of ATP, and, 
as shown in Drosophila, a reduction in mitochondrial fission due to DNM1L (known as Drp1 
in Drosophila) mutation results in elongated mitochondria, with a reduction of synapse 
formation and synaptic dysfunction.
115 
Recently it has been shown that overexpression in neuroblastoma cells of wild-type 
PARK7/DJ-1, a putative sensor of oxidative stress (mutations in which cause autosomal 
recessive PD), results in mitochondrial elongation, whereas PD-associated mutants display 
increased levels of DNM1L and consequently fragmented mitochondria.
116
 Similarly, studies 
of protein expression from Alzheimer disease brain reveal a reduction in the amount of 
DNM1L, OPA1, MFN1 and MFN2 with increased levels of FIS1.
117
 Mimicking these 
expressional changes in neuronal cell culture results in decreased mitochondrial density in 
neuronal processes that could be rescued by DNM1L overexpression. Conversely, excessive 
DNM1L-mediated fission increases apoptosis due to increased cytochrome c release.
118
 
Zebrafish possess homologs of all five of the genes encoding these proteins and so again are 
an excellent system in which to study their function more closely in vivo (Table 1).  
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5. Disease-induced mitophagic defects—PINK1 and PARK2. 
Recent studies have shown that the PINK1-PARK2 pathway is a governor of mitochondrial 
quality control. The finding that mutations in either PINK1 or PARK2 cause autosomal 
recessive PD with mitochondrial defects has highlighted the role of mitochondria in the 
pathogenesis of common neurological disorders, and is providing insight into the 
mechanisms of mitophagy. PINK1 encodes a serine/threonine kinase that is constitutively 
synthesized and localized to mitochondria where it is normally cleaved and degraded.
83
 
PINK1 accumulates on the outer mitochondrial membrane in response to depolarization and 
recruits PARK2, an E3 ubiquitin ligase that under normal conditions is cytoplasmically 
localized. PARK2 mediates ubiquitination of itself and other targets
119
 resulting in 
mitochondrial clustering. It has also now been shown that the receptor protein SQSTM1 is 
recruited to clustered mitochondria and acts as a targeting signal for mitophagy, a role 
requiring ubiquitination by PARK2.
85
 Additionally, VDAC1 (voltage dependent anion 
channel 1) has been identified as a target of PARK2-mediated ubiquitination. Polyubiquitin 
chains on VDAC1 do not attract the proteasomal machinery, but instead attract SQSTM1 
(Fig. 3a). siRNA-mediated knockdown of VDAC1 in HeLa cells results in significantly 
reduced mitochondrial clearance in response to CCCP treatment, demonstrating that VDAC1 
is required for mitophagy.
85
 
 Drosophila Pink1 mutants exhibit grossly enlarged mitochondria
120
 with fragmented 
cristae, sensitivity to oxidative stress
121
 and a slightly reduced number of dopaminergic 
neurons. Moreover, ATP levels are dramatically reduced indicating abnormal mitochondrial 
function.
121
 The phenotypes of Pink1 and Park (the Drosophila PARK2 ortholog) mutants 
are markedly similar,
121-123
 and epistasis experiments
120,124
 indicate that Pink1 acts upstream 
of Park in a common pathway that maintains mitochondrial integrity. Pink1 localizes to 
mitochondria, with its kinase domain facing the cytoplasm. This is required to recruit Park to 
damaged mitochondria to promote their clearance. Several studies have shown that another 
 20 
substrate for ubiquitination by Park is Marf (the Drosophila ortholog of MFN2),
110,111
 which 
is then removed from the mitochondrial membrane by the AAA-ATPase VCP/p97 (valosin 
containing protein) and degraded by the UPS (Fig. 3b).
125
 In SH-SY5Y cells, the loss of 
MFN2 renders mitochondria unable to undergo fusion and so they are subsequently removed 
by mitophagy, a phenomenon that can be rescued by inactivation of DNM1L.
126
 It is 
therefore suggested that in PD, mutant PARK2 contributes by failing to trigger the removal 
of dysfunctional mitochondria by both mitophagy and the UPS (Fig. 3). 
  The fact that PARK2 encodes an E3 ubiquitin ligase, an enzyme responsible for 
tagging proteins destined for degradation by the UPS, implies that toxicity may be related to 
the accumulation of poorly degraded proteins. This may also explain the failure of PARK2 
mutant patients to form Lewy bodies. Assuming that Lewy bodies are protective, their 
absence may accelerate the disease course.  
 Fusing enhanced GFP with the mitochondrial localization signal of cytochrome c 
oxidase subunit VIII has allowed the development of a transgenic zebrafish expressing GFP-
targeted mitochondria.
127
 Using this line, several apoptosis-inducing agents have been tested 
and mitochondrial fragmentation subsequently observed using confocal imaging in real-time 
and in vivo. Should these transgenic fish be crossed with other transgenics, such as that 
expressing human PARK2 (which also expresses dsRed)
128
 for example, then a powerful tool 
for the observation of mitophagy in PD pathogenesis will have been developed. Similarly, 
the generation of a line containing GFP-tagged mitochondria crossed with a line containing a 
fluorescent lysosomal transgenic reporter
19
 may prove useful for the study of mitophagy. The 
advantage of a fluorescent mitochondrial zebrafish line over the use of dyes is that these dyes 
are reliant on mitochondrial membrane potential for their accumulation and obviously 
require extra experimental steps. However, it is also the case that relative fluorescence levels 
of these stains have been used successfully as a readout of mitochondrial membrane 
potential
129
 and so the correct tool must be chosen as required.  
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 In zebrafish studies of PD, mitochondrial membrane potential has been tested in 
isolated mitochondria,
128,130
 but no study of mitochondrial dynamics or mitophagy was 
carried out prior to their isolation, and so it is suggested that further experiments may prove 
informative. Gross morphological analysis has been carried out on mitochondria in some 
zebrafish models of PD,
128,131
 but these did not show any abnormalities. It is possible that 
analysis in morphants is too early to observe gross morphological defects in mitochondria, 
but that these arise over a longer time course as a result of compromised mitochondrial 
function. In order to determine if this is indeed the case, stable knockout lines of both pink1 
and park2 are required. Bandmann et al.
132
 have reported the discovery of a pink1 mutant by 
TILLING. This mutant has a premature stop codon in exon 7 (Y431X). This mutant does not 
display any locomotor problems, although at 5 dpf a significant reduction in the number of 
tyrosine hydroxylase (TH)-positive cells and a reduction in mitochondrial activity have been 
shown. To our knowledge mitophagy has not been investigated in this mutant.  
5.1 Manipulations of park2 in zebrafish. 
The zebrafish Park2 protein shares 62% identity to the human protein, rising to 78% identity 
in functionally relevant regions.
131
 The gene structure of zebrafish park2 is identical to that 
of human PARK2, consisting of 12 exons. In 2009, Flinn et al.
131
 developed a zebrafish 
park2 knockdown model by MO, which produced very interesting results (Table 3). The MO 
resulted in a 51 amino acid deletion disrupting the in-between ring domain required for 
ubiquitination of some proteins. Other domains, including the ubiquitin ligase domain and 
two RING domains, remained intact and so the protein may have some residual enzymatic 
function.
131
 It was shown that by 3 dpf, zebrafish park2 morphants display a reduction in 
dopaminergic neurons of ~20% in the diencephalon.
131
 These zebrafish also display an ~45% 
reduction in the activity of mitochondrial respiratory chain complex I; this corroborates well 
with the view that complex I function is specifically lost in human PARK2-related PD and 
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sporadic PD.
133
 Treatment of park2 knockdown zebrafish with MPP+ (1-methyl-4-
phenylpyridinium) results in ~50% reduction in diencephalic dopaminergic neuronal loss.
131
 
Unfortunately, however, these zebrafish do not display significant locomotor impairment as 
measured by observation of swimming behavior at 5 dpf. As with human patients, it may be 
that a threshold of dopaminergic neuron loss must be reached before locomotor problems 
manifest. Drosophila Park mutants display muscle cell apoptosis, as well as swollen 
mitochondria and disordered cristae in energy sensitive tissues, including the male germ-line 
and adult flight muscle.
134
 These features are not, however, found in the mitochondria of 
striatal neurons in mouse knockout models,
135
 and similarly transmission electron 
microscopy of mitochondria from the fast muscles of park2 knockdown zebrafish embryos 
show no such features, but do display electron dense material in the T-tubules.
131
 These T-
tubules are rich in L-type Ca
2+ 
channels similar to that of the dopaminergic neurons of the 
substantia nigra pars compacta, which utilize high Ca
2+ 
currents for pacemaking. Both the 
increased need to pump Ca
2+
 back out of the neuron, and for mitochondria to buffer excess 
Ca
2+
, may cause mitochondrial stress.
131
 It is possible that swimming behavior and 
mitochondrial morphology are not altered until later in the disease process, which due to the 
transient nature of MO activity cannot be tested in this model. Importantly, it may also be the 
case that these data point to the fact that Park2 has additional roles to those relating to 
mitochondrial function, or that mitochondrial dysfunction is not causative but an 
epiphenomenon of advanced disease. It will therefore be important to generate a stable park2 
knockout zebrafish line, which may present the first successful vertebrate model of PARK2 
mutant patients. Should this be combined with other fluorescent lines, then zebrafish will 
provide a way of studying autophagy and mitochondria in ways not possible in other 
systems.  
 PARK2 is protective against cellular stress and is upregulated as a consequence. To 
clarify whether this is also the case in zebrafish, Fett et al.
128
 treated a zebrafish cell line 
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called Pac2 with rotenone. RT-PCR revealed a two-fold expression increase of park2 
mRNA. Furthermore, SH-SY5Y cells transiently expressing zebrafish Park2 are protected 
against kainite-induced excitotoxicity.
128
 Antisense gripNA
TM
 targeting the exon-intron 
junction of park2 exon 2 was used by the same group to knock down park2, resulting in a 
53% reduction in Park2 protein.
128
 No morphological or behavioral alterations were detected 
and the number of dopaminergic neurons was also unaffected; considering the fact that in 
human, PARK2 mutations are recessive, it is likely that a 50% reduction in PARK2 is not 
deleterious, and so this result is not unexpected.  
 To confirm if the neuroprotective capacity of Park2 demonstrated in vitro was 
evident in vivo, a human PARK2-overexpressing transgenic zebrafish model was created 
using a GAL4-VP16/UAS PARK2-dsRed bidirectional expression system
128
 (Table 3). 
Under normal developmental conditions, quantification of apoptotic cells in the transgenic 
did not differ from that of controls, whereas park2 knockdowns showed a slight increase in 
apoptotic cells.
128
 A heat shock approach whereby 2 dpf embryos were incubated at 39°C for 
1 h was used to determine if a proteotoxic stress might confirm a protective effect of 
PARK2. Apoptosis is increased in the park2 knockdown zebrafish compared to wild-type 
controls, whereas in the transgenic a significant reduction in apoptosis was shown.
128
 This 
study again exemplifies the advantage of zebrafish over mammalian models, in that it is 
possible to watch the cells expressing the protein of interest and, in combination with the use 
of vital stains, observe subcellular processes active in those particular cell types.  
5.2 Manipulations of pink1 in zebrafish. 
Zebrafish pink1 consists of 8 exons, identical to that of human, and encodes a 574 amino 
acid protein with 54% identity to human. Functional protein sequence prediction shows an 
N-terminal mitochondrial targeting sequence and a C-terminal serine-threonine kinase 
domain, confirming its similarity to the human protein.  
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 To further elucidate the role of PINK1 in PD, a zebrafish MO knockdown model has 
been generated
130
 (Table 3). In this study, the morphants showed a developmental 
abnormality, which leads to neurodegeneration. Anti-acetylated tubulin 
immunohistochemistry revealed less prominent commissures, and disorganization of the 
paramedial descending axonal tract in the hindbrain and spinal cord was also observed.
130
 
With relevance to the human PD phenotype, TH-positive dopaminergic neurons in the 
diencephalon are significantly reduced in number, whereas serotonergic neurons are 
unaffected. In the same study, in situ hybridization probes for park2 and reelin (a general 
marker of neurons) demonstrate reduced expression, while that of fezl and neurogenin 1 is 
upregulated. Fezl is required for the development of dopaminergic neurons and acts 
upstream of neurogenin 1. This therefore suggests an attempted compensatory action. 
Importantly, motor defects are observed by loss of escape response at 72 hpf. Further 
confirmation that pink1 is homologous to human was provided by the observation that the 
injection of human wild-type PINK1 mRNA partially rescues the MO phenotype, including 
reversal of the lost escape response. Injection of human PINK1 mRNA with either the PD 
mutations A168P or W437X fails to rescue the MO phenotype.
130
 These mRNA rescue 
experiments highlight the utility of the zebrafish model to validate homologous genes using 
simple micro-injection techniques, again offering an advantage over mammalian systems.  
 Interestingly, Xi et al.
136
 were unable to replicate a significant reduction in 
dopaminergic, ventral diencephalic neurons in a pink1 knockdown zebrafish model (Table 
3). This model did, however, display altered patterning and projection of these neurons with 
a concomitant locomotor defect.  
 Due to the fact that pink1 morphants show a short tail phenotype similar to that of the 
wnt mutant pipe tail, it was hypothesized that beta catenin levels would be depleted and that 
glycogen synthase kinase 3 beta (Gsk3b) would be upregulated, both consequences of wnt 
inhibition.
130
 Treatment of the morphants with a nonspecific Gsk3b inhibitor, or the specific 
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inhibitor SB216763, rescues ~20% of morphants with the short tail phenotype and causes a 
rise in the levels of beta catenin, thus confirming the involvement of the wnt pathway. These 
findings may converge with the possible role of LRRK2 in WNT signalling
137
 and therefore 
indicate a common route to the neurodegeneration characteristic of PD. LiCl treatment does 
not, however, improve the loss of dopaminergic neurons in the morphant brain. This 
suggests that Gsk3b may play a role in the peripheral phenotypes observed, but that other 
factors are involved in the dopamine neuron loss. Further study of Wnt signalling, the known 
pink1 mutant
132
 and generation of another pink1 knockout model is therefore recommended.  
 The observed rise in Gsk3b levels also appears to play a role in the increased level of 
apoptosis present throughout the morphants, as shown by acridine orange staining. Again, 
LiCl treatment reduces the activity of Casp3, an activator of the effector caspases of the 
apoptotic cascade. Mitochondria isolated from morphants at 24 hpf incubated with 5,5,6,6’-
tetrachloro-1,1’,3,3’ tetraethylbenzimidazolylcarbocyanine iodide (JC-1), a dye used to 
detect mitochondrial membrane potential, showed a reduction in membrane potential and an 
increase in ROS. LiCl treatment did not rescue the loss of membrane potential, but did 
reduce the ROS levels.
130
 These data collectively suggest the possibility that Gsk3b 
inhibitors and antioxidants may present as possible therapeutic agents that could be 
successfully tested in zebrafish models.  
 The PINK1-PARK2 pathway has also been linked to mitochondrial dynamics, a 
factor of particular importance in neurons. In rat neurons, mitochondrial depolarization 
results in PINK1-PARK2 interaction with a Rho-GTPase called RHOT1 (alias Miro1), a 
protein that anchors kinesins to mitochondria.
138
 PINK1 first phosphorylates RHOT1, which 
is then tagged with ubiquitin by PARK2 prior to its degradation. The loss of RHOT1 
prevents the movement of mitochondria, thus segregating them for removal.
139
 Whether or 
not RHOT1 is essential for mitophagy has yet to be elucidated. To take these experiments 
further in order to try and link the PINK1-PARK2 pathway to mitochondrial dynamics and 
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mitophagy, live imaging of fluorescently-tagged mitochondria and, for example, their 
trafficking along microtubules using a stain such as Tubulin Tracker Green, could be 
performed. 
 
 6. Defects of the respiratory chain produce ‘Parkinsonism’ and mitochondrial 
fragmentation. 
The mitochondrial respiratory chain comprises five protein complexes, and defects of this 
pathway can potentially cause disease.
140
 Mitochondria have been associated with 
neurodegenerative disease for some time, the research of which has focussed on the role of 
complex I in PD. The inhibitor of complex I, 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine 
(MPTP), induces Parkinsonian-like clinical and neuropathological signs in humans and 
nonhuman primates.
141
 MPTP is converted to MPP+ by the enzyme MAOB (monoamine 
oxidase B). It is this metabolite that is taken up by SLC6A3/DAT [solute carrier family 6 
(neurotransmitter transporter, dopamine), member 5/dopamine active transporter] and is 
neurotoxic. Incubation of larval zebrafish in MPTP or application of MPP+ directly, induces 
progressive dopamine neuron loss in the posterior tuberculum, and a paucity of reflex 
response to touch with reduced escape velocity and swimming distance
142
 (Table 3). This 
toxicity is mediated by the same mechanisms as in humans, as shown by the observation that 
L-deprenyl (an inhibitor of MAOB), the SLC6A3 inhibitor nomifensine, and MO 
knockdown of the SLC6A3 all protect neurons from MPTP damage.143 It has also been 
shown that rotenone, another complex I inhibitor, produces dopaminergic cell loss, and 
complex I deficiency is reduced in cells derived from PD patients.
144
 Complex I inhibition is 
also associated with mitochondrial fragmentation that can be rescued in SH-SY5Y cells 
either by inhibition of DNM1L or overexpression of MFN1.
145
  
 An important consequence of complex I inhibition is the proportional increase in 
production of ROS
146
 due to restricted electron transfer. Interestingly, zebrafish are often 
 27 
incubated in methylene blue, a drug used to inhibit fungal growth during development. 
Methylene blue is an alternative electron carrier that can bypass complex I blockade; in rats 
it has been shown to attenuate rotenone-induced mitochondrial dysfunction.
147
 If zebrafish 
mitochondrial research is being conducted it may be that methylene blue use is best 
eliminated to avoid confounding results.  
 Methylene blue has been tested on a zebrafish transgenic model of TAU-P301L, a 
mutation causative of frontotemporal dementia with Parkinsonism
148
 (Table 3). However, 
neither abnormal TAU phosphorylation nor misfolding of TAU is significantly different to 
that of the non-drug treated group. In this same study, methylene blue failed to rescue 
neuronal cell death, improve swimming behavior or rescue the axonal outgrowth of 
motoneurons. The implications of these findings are that methylene blue does not inhibit 
aberrant kinase activity and that the abnormal phosphorylation of TAU is likely to cause its 
misfolding. Although in a phase 2 clinical trial in Alzheimer patients
148
 a significant 
improvement in cognition was observed, it seems the mechanism of action is unlikely to be 
through the inhibition of the proposed TAU aggregation. It may be the case that the drug acts 
through its effect on mitochondria or that it is a regulator of autophagy; both of these 
possibilities could be explored further in zebrafish by, for example, assessing the levels of 
transcripts from genes involved in autophagy, or by following the process with vital stains.  
 Given these negative results it is possible that methylene blue (or any other 
compound with a negative result) may not be well absorbed by the zebrafish. This would 
appear not to be the case with methylene blue due to the fact that in a further study, zebrafish 
expressing mutant human TARDBP and FUS, causative of some types of amyotrophic 
lateral sclerosis, methylene blue was shown to be beneficial
149
 (Table 3). In this study, motor 
activity was partially rescued, as was the abnormal motoneuron morphology. In addition, it 
was shown that methylene blue was protective of oxidative stress, and so highlights the use 
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of zebrafish to test disease-modifying compounds and illustrates the promise of methylene 
blue as a neuroprotective agent in specific cases.  
7. Conclusion. 
 
Mitophagy has now been established as a mechanism to regulate mitochondrial health, and 
mitochondrial dysfunction is involved in a number of neurodegenerative diseases. The 
molecular machinery of autophagy and mitophagy is becoming better understood, largely 
through yeast studies, but there remains a need to identify more of the proteins involved and 
to understand the process more fully in higher organisms. Zebrafish are a well-established 
tool of the developmental biology field, but their potential has yet to be fully realized as a 
human disease model. Although the use of MOs to knock down genes of interest is a very 
powerful tool, fundamental to the success of zebrafish models will be the development of 
more transgenic lines, particularly human disease gene knockins. It is hoped that through 
these models, a greater understanding of the underlying pathological processes, such as that 
of altered mitochondrial dynamics, can be elucidated. Additionally, zebrafish are an 
excellent organism in which to validate potential modulators of mitophagy in vivo, and bring 
the use of new therapeutic compounds closer to the bedside faster and more cheaply than has 
previously been possible.  
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Figure 1. Alignment of human PINK1 protein with zebrafish Pink1 protein. It can be seen 
that amino acid conservation is higher in the kinase domain (higher density of black bars) 
containing important interaction sites (purple arrows). Secondary structure prediction also 
shows high similarity of motifs. PKc – protein kinase domain. It should be noted that the 
conservation of amino acid residues is higher in functional domains as compared to the total 
protein. For example, MUSCLE alignment of the human PINK1 protein against zebrafish 
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Pink1 produces an identity of 54%; however, aligning just the kinase domain results in an 
alignment of 71%.  
 
Figure 2. Schematic of the zebrafish dopaminergic system in 3 dpf old larvae. ac, anterior 
commissure; act, anterior catecholamine tract; AP, area postrema; CH, caudal hypothalamus; 
DC, diencephalic cluster; eht, endohypothalimc tract; hhp, hypothalamic-hypophyseal 
projections; lcp, lateral catecholaminergic projections; mlct, medial longitudinal 
catecholaminergic tract; MO, medulla oblongata; OB, olfactory bulb; obla, olfactory bulb 
local arbors; pc, posterior commissure; PO, preoptic region; poht, posterior hypothalamic 
tract; Pr, pretectum; prp, pretectal projections; Prtep, pretectal tectoprojections; nos. 1-6 
ventral diencephalic cluster. Adapted from Kastenhuber et al.
37
 
 
Figure 3. The PINK1-PARK2 pathway to mitophagy. (A) PARK2 ubiquitinates VDAC1, 
which attracts SQSTM1, a targeting signal for mitophagy. (B) Upon mitochondrial 
depolarization, PINK1 accumulates on the outer mitochondrial membrane to recruit PARK2. 
PARK2 ubiquitinates MFN1/2, which are removed by VCP and degraded by the UPS. Loss 
of MFN1/2 inhibits mitochondrial fusion, so that mitochondria are removed by mitophagy.  
 
 
Table 1. Zebrafish orthologs of genes involved in mitophagy. 
 
Human 
protein 
Function Action Zebrafish 
orthologous 
gene 
Protein 
identity 
(%) 
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(ClustalW) 
BCL2 Pro-survival 
apoptosis 
regulator 
Inhibits autophagy bcl-2 46.0 
BCL2L1 Pro-survival 
apoptosis 
regulator 
Inhibits autophagy; 
regulates VDAC 
bcl2l-1 51.7 
BNIP3L  Putative 
mitophagy 
receptor 
Interaction with 
MAP1LC3/GABARAP; 
recruits autophagic 
machinery 
bnip3la 
bnip3 
46.4 
69.5 
DNM1L Outer membrane 
fission 
Regulates 
mitochondrial fission 
dnml-1 90.0 
FIS1 Outer membrane 
fission 
Regulates 
mitochondrial fission 
fis1 67.8 
MFN 1 
MFN2 
Outer membrane 
fusion 
Ubiquitinated by 
PARK2; MFN1/2 Ub-
dependent degradation 
precedes mitophagy 
induction 
mfn1 
mfn2 
68.4 
83.0 
SMCR7L Outer membrane 
fusion 
Recruits DNM1L to 
outer membrane; 
promotes fusion 
smcr7a 69.9 
OPA1 Inner membrane 
fusion 
Regulates 
mitochondrial fusion 
opa1 82.6 
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PARK2 E3 ubiquitin 
ligase 
Ubiquitinates MFN1/2, 
VDAC1 
park2 62.0 
PINK1 Serine/threonine 
protein kinase 
 
Phosphorylates PARK2 
and recruits it to 
mitochondria 
pink1 53.7 
SQSTM1 Receptor protein 
 
Interacts with 
ubiquitinated proteins to 
recruit autophagic 
machinery 
sqstm1 35.9 
VDAC1 Voltage 
dependent anion 
channel, outer 
mitochondrial 
membrane 
Ubiquitination by 
PARK2 induces 
recruitment of 
autophagic machinery 
 
vdac1 85.5 
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Table 2. Useful resources for sourcing mutant zebrafish lines and understanding anatomy 
and gene expression. 
Resource Web link Information available 
Zebrafish 
Information 
Resource 
Centre 
http://zebrafish.org/zirc/fish/lineAll.php Genotype/phenotype 
information and line 
availability. 
Zebrafish 
Mutation 
Project 
http://www.sanger.ac.uk/Projects/D_rerio/zmp
/ 
Information on all knockout 
lines. Possible to search by 
human ortholog. 
Tübingen 
zebrafish 
stock 
collection 
http://www.eb.tuebingen.mpg.de/research/dep
artments/genetics/zebrafish-stock-
collection.html 
Information on all available 
mutant lines available. Will 
also perform IVF on 
request. 
FHCRC 
Zebrafish 
TILLING 
Project 
http://www.zfishtilling.org/fhcrc/ Information on all mutants 
so far found. Request for 
genes to be screened by 
TILLING can be submitted. 
ZF-Models http://www.sanger.ac.uk/Projects/D_rerio/zf-
models.shtml 
List of all knockout lines 
and request genes to be 
screened by TILLING. 
Zebrafish 
Brain Atlas 
http://www.ucl.ac.uk/zebrafish-
group/zebrafishbrain/index.php 
Multimedia anatomical 
resource. Further links are 
provided to other useful 
resources including imaging 
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protocols. 
ZFIN http://zfin.org/cgi-bin/webdriver?MIval=aa-
ZDB_home.apg 
Zebrafish model organism 
database. Comprehensive 
information available on all 
aspects of zebrafish 
research.  
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Table 3. Overview of the key findings attained from zebrafish models of neurodegenerative 
disease.  
Disease Type of model Protein Outcome summary Reference 
Tauopathy 
  
 
 
 
 
 
Transgenic 
 
 
 
 
4R TAU-GFP 
fusion 
 
 
 
 
 
4R/0N TAU 
Neuronal 
expression. TAU 
accumulations, 
tangles.  TAU 
phosphorylation.  
No stable line.  
  
Neuronal 
expression. TAU 
accumulations, 
tangles. 
Tomasiewicz et 
al. 2002 
 
 
 
 
 
Bai et al. 2007 
FTDP-17 
 
Transgenic 
 
TAU P301L 
 
Motor axonal 
outgrowth delay.  
Loss of escape 
response.  
Apoptosis in spinal 
cord.  TAU 
phosphorylation.  
TAU aggregation.   
 
Methylene blue 
treatment of this 
Paquet et al. 
2009 
 
 
 
 
 
 
 
vanBebber et 
al. 2010 
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model failed to 
reduce any of the 
phenotypes. 
Alzheimer Morphant Appa/b Defective 
conversion-
extension 
movements.  Not 
rescued by 
APPswe.   
Joshi et al. 2009 
Alzheimer Transgenic Amyloid beta 42 Melanophore 
expression resulted 
in aberrant 
phenotype at 16 
months. 
Newman et al. 
2010 
Huntington 
 
 
 
 
 
 
 
 
 
 
Transient over-
expression 
 
 
 
 
 
 
 
 
 
HTT Q102-GFP 
 
 
 
 
 
 
 
 
 
 
Protein 
aggregation.  
Apoptotic cells 
lacked inclusions. 
Increased 
embryonic 
lethality. Hsp40 
and Hsp70 
suppressed polyQ 
aggregation and 
toxicity.  Two 
Schiffer et al. 
2007 
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Transient over-
expression 
 
 
 
 
Transgenic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HTT Q102-GFP 
 
 
 
 
 
HTT Q71-GFP 
 
 
 
 
 
 
 
 
 
 
 
 
compounds of the 
N-benzylidene-
benzohydrazide 
class inhibited 
aggregation. 
 
Methylene blue 
treatment reduced 
aggregates but 
failed to protect 
against toxicity. 
 
Mutant huntingtin 
expressed in rod 
photoreceptors.  
Forms aggregates 
and reduced 
rhodopsin 
expression.  
Several 
compounds tested 
that reduce 
aggregates and 
increase rhodopsin 
expression.   
 
 
 
 
 
 
vanBebber et 
al. 2010 
 
 
 
 
Williams et al. 
2008 
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Transgenic 
 
 
 
 
 
 
 
 
 
Morphant 
 
 
 
 
 
 
 
 
 
Transgenic 
HTT Q71-GFP 
 
 
 
 
 
 
 
 
 
Htt 
 
 
 
 
 
 
 
 
 
HTT Q71-GFP 
 
Nitric oxide, an 
inhibitor of 
autophagy was 
inhibition by L-
NAME 
successfully 
reducing 
huntingtin 
aggregates. 
 
Variety of 
developmental 
defects.  Most 
notably 
hypochromic 
blood.  Suggested 
role of Htt in 
utilization of 
endocytosed iron.  
 
Antioxidants 
increased the 
number of mutant 
huntingtin 
aggregates. 
Sarkar et al. 
2011 
 
 
 
 
 
 
 
 
Lumsden et al. 
2007 
 
 
 
 
 
 
 
 
Underwood et 
al. 2010 
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ALS Transient over-
expression 
 
Transient over-
expression 
 
 
 
 
 
 
 
Transgenic 
 
 
 
 
 
 
Transgenic 
SOD1 
 
 
SOD1 A4V 
SOD1G93A 
SOD1G37R 
 
 
 
 
 
 
Sod1 G93R 
 
 
 
 
 
 
Sod1 
No phenotype. 
 
 
Abnormal length 
and branching of 
motor neurons.  
Rescued by 
upregulation of 
Vegf and 
exacerbated by 
MO of Vegf.  
 
Larval NMJ defect, 
late stage muscle 
atrophy, decreased 
endurance, 
paralysis and 
premature death. 
 
No phenotype 
Lemmens et al. 
2007 
 
Lemmens et al. 
2007 
 
 
 
 
 
 
 
Ramesh et al. 
2010 
 
 
 
 
 
Ramesh et al. 
2010 
 
ALS Transient over-
expression 
 
TARDBP G348C 
TARDBP A315T 
 
Abnormal length 
and branching of 
motor neurons.  
Kabashi et al. 
2010 
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Transient over-
expression 
 
 
Morphant 
 
 
 
 
 
 
 
Transgenic 
 
 
 
 
 
 
 
Transgenic 
 
 
 
 
TARDBP A382T 
 
 
 
Tardbp 
 
 
 
 
 
 
 
TARDBP G348C 
 
 
 
 
 
 
 
FUS R521H 
 
Motor deficit. 
 
Abnormal motor 
axon length.  
Motor deficit. 
 
Abnormal length 
and branching of 
motor neurons.  
Motor deficit.  
Rescued by WT 
TARDPB but not 
mutant forms. 
 
Motor deficit.  
Abnormally 
shortened and 
branched motor 
neuron axonal 
processes. Rescued 
by methylene blue. 
 
Motor deficit.  
Abnormally 
shortened and 
 
 
Kabashi et al. 
2010 
 
 
Kabashi et al. 
2010 
 
 
 
 
 
 
Vaccaro et al. 
2012 
 
 
 
 
 
 
Vaccaro et al. 
2012 
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branched motor 
neuron axonal 
processes. Rescued 
by methylene blue. 
ALS Morphant Alsin Swimming 
deficits, motor 
neuron 
perturbation.   
Gros-Louis et 
al. 2008 
Spinal 
Muscular 
Atrophy 
Morphant 
 
 
 
 
TILLING 
mutant 
 
 
Smn1 
 
 
 
 
Smn1 
 
 
Truncated spinal 
motor neurons 
with increased 
axonal branching.   
 
Reduction in levels 
of synaptic vesicle 
protein SV2 at the 
NMJ.  Rescued by 
human SMN1. 
McWhorter et 
al. 2003 
 
 
 
Boon et al. 
2009 
Hereditary 
Spastic 
Paraplegia 
Morphant Spastin Much reduced 
motor axonal 
projections.  
Aberrant migration 
of some motor 
neuron 
populations.  
Wood et al. 
2006 
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Apoptosis of spinal 
motor neurons.  
Impaired 
swimming.  
Disordered 
microtubules.   
Parkinson 
Disease 
Morphant 
 
 
 
 
 
 
 
 
Antisense GT-
gripNA
TM 
 
 
 
 
 
 
Transgenic 
 
 
Park2 
 
 
 
 
 
 
 
 
Park2 
 
 
 
 
 
 
PARK2 
 
 
Complex I activity 
reduced.  
Dopaminergic cell 
loss.  Increased 
sensitivity to 
MPP
+
.  Abnormal 
T-tubules.  No 
locomotor defect.   
 
50% knockdown.  
No developmental 
phenotype.  
Increased 
susceptibility to 
cellular stress. 
 
Increased 
resistance to 
cellular stress.   
Flinn et al. 
2009 
 
 
 
 
 
 
 
Fett et al. 2010 
 
 
 
 
 
 
Fett et al. 2010 
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Morphant 
 
 
 
 
 
 
 
 
 
Morphant 
 
 
 
 
 
 
Morphant 
 
 
 
 
 
 
 
Pink1 
 
 
 
 
 
 
 
 
 
Pink1 
 
 
 
 
 
 
Pink1 
 
 
 
 
 
 
 
Decreased 
numbers of 
dopaminergic 
neurons.  Altered 
mitochondrial 
function.  
Elevation of Gsk3b 
activity.  Loss of 
escape response.   
 
Reduction in Th 
expression.  
Increased 
sensitivity to 
MPTP.  Locomotor 
deficit.   
 
Minimal alteration 
in number of 
dopaminergic 
neurons.  Altered 
patterning and 
projection of 
dopaminergic 
 
Anichtchik et 
al. 2008 
 
 
 
 
 
 
 
 
Sallinen et al. 
2010 
 
 
 
 
 
Xi et al. 2010 
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TILLING 
mutant 
 
 
 
 
 
 
 
 
Pink1 
neurons in ventral 
diencephalon.  
Locomotor 
dysfunction. 
 
Reduced Th 
positive cells.  
Reduction in 
mitochondrial 
complex I activity.   
 
 
 
 
 
Bandmann et 
al. 2010 
Parkinson 
Disease 
Morphant Park7 Loss of 
dopaminergic 
neurons after 
exposure to 
hydrogen peroxide 
and the proteasome 
inhibitor MG132.  
Increased tp53 and 
Bax expression 
prior to toxin 
exposure.     
Bretaud et al. 
2007 
Parkinson 
Disease 
Morphant Lrrk2 Significant loss of 
dopaminergic 
neurons in the 
ventral 
Sheng et al. 
2010 
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diencephalon.  
Reduced and 
disorganized axon 
tracts in the 
midbrain.  
Locomotor defect.   
Parkinson 
Disease 
Pharmacological 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmacological 
 
 
 
 
N/A 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/A 
 
 
 
 
MPTP or 6-OHDA 
injection reduces 
dopamine 
concentration in 
the brain.  No 
significant 
reduction in 
dopaminergic 
neuron number.  
No increase in 
apoptotic cells.  
Marked locomotor 
deficits.   
 
Transgenic line 
developed 
expressing GFP in 
monoaminergic 
neurons.  MPTP 
Anichtchik et 
al. 2004 
 
 
 
 
 
 
 
 
 
 
 
 
Wen et al. 2008 
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Pharmacological 
 
 
 
 
 
 
 
 
N/A 
exposure reduces 
number of Th 
positive neurons in 
posterior 
tuberculum of 
ventral 
diencephalon.   
 
Zebrafish larvae 
subjected to either 
MPTP or MPP+ 
demonstrated 
swimming defects 
and perturbed 
development of 
SLC6A3-positive 
diencephalic cells. 
 
 
 
 
 
 
 
 
Lam et al. 2005 
 
 
 
 
 
